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Abstract
Background: Thalamic hemorrhage (TH) is a neurological insult with a high rate of morbidity and mortality.
Moderate TH (10–30 ml) accounts for more than half of all TH. Treatment remains controversial. The role of
acupuncture in patients with moderate TH is not clear.
Methods: We will conduct a single-center, randomized, parallel group, and assessor-blinded clinical trial. A total of
488 patients with moderate TH will be randomly assigned to one of eight groups: 10–15 cc left sided TH study
group (N = 61) and a corresponding control group (N = 61), 10–15 cc right sided TH study group (N = 61) and a
corresponding control group, 15–30 cc left sided TH study group (N = 61) and a corresponding control group
(N = 61), and 15–30 cc right sided TH study group (N = 61) and a corresponding control group. Study groups will
receive acupuncture in addition to standard treatment, while control groups will receive standard treatment
alone. The primary outcome will be change in National Institutes of Health Stroke Scale scores at 30 and 90 days
after TH. The secondary outcomes will be death or major disability, defined as a score of 3 to 6 on the modified
Rankin scale (in which a score of 0 indicates no symptoms, a score of 5 indicates severe disability, and a score of
6 indicates death) at 90-days, need for surgery at 30-days, Glasgow Outcome Scale (GOS) score at 90-days
following TH onset, and the results of several additional group specific tests. The rate of adverse events will then
be compared between the groups.
Discussion: This study will attempt to answer the question of whether or not acupuncture can improve
neurologic outcome following moderate TH.
Trial registration: Chinese clinical trial registry (ChiCTR-IOR-16008362)
Keywords: Acupuncture, Intracranial hemorrhage, Moderate thalamic hemorrhage, RCT
Background
Spontaneous intracerebral hemorrhage (ICH), non-
iatrogenic ICH without trauma, is the second most
common and the most devastating form of all strokes
with the poorest prognosis [1, 2]. Approximately 15%
of all cases of spontaneous ICH occur in the thal-
amus [3–5]. The thalamus is a deep brain structure
and is an important center for the transmission of
neural signals [3, 6]. Due to its anatomical location
and the vital functions that it performs, the decision
of conservative or surgical management for TH remains
controversial [2, 7, 8]. Management is influenced mainly
by the clinical experience of the treating surgeon and the
volume of the hematoma [9]. Patients with minor TH,
especially volumes less than 10 cc, usually obtain favorable
outcomes when treated with conservative measures. How-
ever, patients with major TH, greater than 30 cc, have
mortality rates of more than 80%, no matter what treat-
ment is selected [10]. Moderate TH (10–30 mL) consti-
tutes more than half of all cases of TH, and these patients
have a mortality rate of more than 30% [11]. As moderate
TH is the most common form of TH, its prognosis carries
the greatest weight in calculating the prognosis of all
forms of TH. In patients with moderate TH, conservative
* Correspondence: zhenjiuhuaxi@163.com
1Department of Integrated Traditional and Western Medicine, West China
Hospital, Sichuan University, Chengdu, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wang et al. BMC Complementary and Alternative Medicine  (2017) 17:112 
DOI 10.1186/s12906-017-1614-6
treatment alone versus surgical treatment is naturally a
difficult decision to make. Because surgical treatment is
invasive, adjacent structures may be damaged and neural
pathways may be disrupted during surgical evacuation of a
hematoma, thereby aggravating the degree of neurologic
deficits or creating new ones. Meanwhile, conservative
treatment alone does not offer the involved thalamic
tissue the same type of relief that evacuation offers and is
therefore felt to be a limited strategy in improving neuro-
logic function. The limitations of both therapeutic strat-
egies provide considerable room for better approaches or
combinations of approaches.
Two recognized mechanisms of brain injury from ICH
have been established [12, 13]. Primary injury happens
at the time of initial hemorrhage when direct damage to
brain tissue occurs either secondary to the hematoma
itself or to its mass effect on surrounding brain tissue.
Secondary injury happens at some time following initial
hemorrhage and includes neuronal death from either the
inflammatory response to the hematoma, the release of
toxic materials and other cytokines, the breakdown of
the brain blood barrier, apoptosis, or the development of
edema. While the pathophysiology of ICH provides
many potential approaches for its treatment, enlargement
of the hematoma and the development of surrounding
edema have been identified as major contributors to the
high morbidity and mortality of ICH and have thus been
the major focus of potential treatment strategies [14–17].
Acupuncture, one of the major branches of Traditional
Chinese Medicine (TCM), has long been used to treat
acute stroke, including hemorrhagic stroke, in China as
well as in many other East Asian countries. Acupunc-
ture’s utility in the treatment of non-hemorrhagic stroke,
which is now documented by the WHO (World Health
Organization, 2002), has been widely researched [18]. In
recent years, a number of studies using modern technolo-
gies have shown that acupuncture may have neuroprotec-
tive effects following hemorrhagic stroke as well [19–22].
One preclinical systematic review of 19 animal studies
showed that GV20 (Baihui) based acupuncture can im-
prove neurologic outcome by regulating the inflammatory
response to a hematoma, inhibiting neuronal apoptosis,
reducing cerebral edema, maintaining ATP supply, pro-
moting nerve regeneration, maintaining neuronal mem-
brane integrity, and promoting hematoma resorption [23].
In another animal study, acupuncture at the DU20 acu-
point was reported to have a neuroprotective effect on
cerebral hemorrhage by inhibiting Notch-Hes signaling in
rat basal ganglia [24]. It has also been reported that
electro-acupuncture treatment at the Zusanli (ST36) acu-
point may accelerate ICH-induced angiogenesis via the
up-regulation of the HIF-1α protein and therefore may
enhance recovery following hemorrhagic cerebral injury
[25]. A separate study confirmed that treatment at the
ST36 acupoint may aid recovery following central nervous
system intracerebral hemorrhage in rats [26]. Although
animal studies have led to progress in determining how
acupuncture exerts its benefits in the treatment of acute
hemorrhagic stroke, the determination of its clinical value
remains incompletely assessed [27–30].
To our knowledge, no organized study has reported
on the effects of acupuncture in patients with acute
moderate TH. Specifically, no prior study has exam-
ined whether or not the use of acupuncture combined
with conventional treatments improves the prognosis




We hypothesize that the addition of acupuncture to
conventional treatments will improve neurological
prognosis in TH patients. To test this hypothesis, we
will compare study and control groups created based
on the size and side of the TH. The study groups will
receive acupuncture in addition to standard treat-
ments, while the control groups will receive standard
treatments alone.
Study design
This study will be a single-center, randomized, placebo-
controlled, parallel group, and patient-assessor-blinded
clinical trial. After completing informed consent, 488
eligible patients will be recruited and randomized to
one of eight groups: 10–15 cc left sided TH study
group (N = 61) and a corresponding control group (N = 61),
10–15 cc right sided TH study group (N = 61) and a corre-
sponding control group, 15–30 cc left sided TH study
group (N = 61) and a corresponding control group (N = 61),
and 15–30 cc right sided TH study group (N = 61) and a
corresponding control group. The patients in each of the
study groups will receive 36 sessions of Chinese acupunc-
ture in addition to standard treatments for TH, which
include anticonvulsant therapy, antihypertensives, osmotic
diuretics for the management of intracranial pressure, and
invasive treatments as necessary. The patients in each of
the control groups will receive standard treatments only.
Patients’ neurologic status will be assessed at baseline and
at the end of treatment as well as at 30 day and 90 day
follow-up intervals. CT imaging will be performed on
admission and at 90 days follow up. All patients will be
required to complete written informed consent prior to
enrollment. If patients are unable to complete written
informed consent, it will be obtained from their relatives. A
flow chart demonstrating an outline of the study is included
in Fig. 1.
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Study setting
This study will be conducted on a neurosurgery unit in
Sichuan University’s West China (Hua Xi) Hospital in
Chengdu, China. With 4300 beds and more than 300
surgical operations per day, the hospital is one of the
largest in China. The neurosurgery department is the
largest in southwest China, with 181 surgical beds, 100
beds for rehabilitation and/or postoperative recovery,
and more than 3800 craniotomies performed per year.
Ethics
This trial will be carried out in accordance with the
ethical standards described in the 2013 updated Declar-
ation of Helsinki. The study was approved by the West
China Hospital, Sichuan University clinical research and
biomedical ethics committees (ethics reference: 2016-
044). Written and signed informed consent will be
obtained from all participants prior to their inclusion in
the study. This trial has also been registered on
www.chictr.org.cn (ChiCTR-IOR-16008362) and will be
reported in compliance with the CONSORT statement
(www.consort-statement.org) [31] as well as STRICTA
(Standards for Reporting Interventions in Clinical Trials
of Acupuncture) [32].
Participants
Patients with moderate TH will be recruited from the
neurosurgery unit at Huaxi Hospital in China. The diag-
nosis of TH and the side of the hemorrhage will be
determined based on computer tomography. TH volume
Fig. 1 The flow chart. Patients in acupuncture group will receive 36 sessions acupuncture treatment, 6 days a weeks for 6 weeks, in addition to
conventional treatments and patients in control group will receive conventional TH treatments only. LSTH, left-sided thalamic hemorrhage; RSTH,
right-sided thalamic hemorrhage
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will be calculated by the neurosurgeon for all patients.
Patients who meet eligibility criteria will be enrolled in
the study, and written informed consent will be obtained
prior to their enrollment.
Subject enrollment
The nurses responsible for the neurosurgery patients at
Huaxi Hospital will be thoroughly educated regarding
moderate TH. Patients and/or their legal guardians will
be able to contact the project leader at any time should
they desire additional information. After obtaining
signed informed consent, the project leader will collect
certain baseline information (including age, diagnosis,
side of hemorrhage (left or right), hematoma volume,
medical history, CT report, etc..) and determine whether
or not the patient meets the eligibility criteria for the
trial or not. Only participants who meet the inclusion
criteria and do not possess any of the exclusion criteria
will be enrolled. A total of 488 patients with TH who are
admitted to the neurosurgical unit of our hospital will
be enrolled in the trial.
Randomization and blinding
Randomization of subjects to the study and control
groups will be computer-generated, using the Package
for Encyclopaedia Medical Statistics 3.1 (PEMS 3.1)
software. Stratified block randomization will not be
performed. Concealed allocation will be achieved by
having an assigned researcher not to have any contact
with patients. Group assignments will be placed in
opaque sealed envelopes. Subjects with 10–15 cc left
TH, 10–15 cc right TH, 15–30 cc left TH, and 15–30 cc
right TH will thus be assigned to either an acupuncture
plus conventional treatment group or a conventional
treatment alone group, in a 1:1 ratio based on the size
and side of their hemorrhage. The primary researchers
will be blinded to the type of intervention that each
patient has received. The acupuncture practitioners will
not provide any clues regarding group assignments to
either the researchers or to the statistician.
Inclusion criteria
Patients with ICH who meet the following inclusion
criteria will be enrolled in the trial:
(1)First ever TH verified by computer tomography (CT)
(2)Moderate TH (10 ~ 30 ml);
(3)Unilateral primary TH;
(4)Hematoma originating and confined to the thalamus;
(5)Age between 18 and 70 years;
(6)Acupuncture treatment can be applied within 72 h
after TH;
(7)Voluntarily willing to sign informed consent.
(8)Right handed.
(9)All bleeding has stopped at the time of
acupuncture initiation.
Exclusion criteria
Patients meeting any of the following criteria will be
excluded from the study:
(1)Traumatic TH;
(2)Bilateral TH;
(3)Hematoma originates in another location and
extends to the thalamus or hematoma originates in
the thalamus and extends beyond the thalamus;
(4)Other areas of cerebral infarction, cerebral
hemorrhage, or tumor on admission CT/MRI;
(5)Unable to determine the location of the origin of the
hematoma on admission CT;
(6)Minor TH (<10 ml) or major TH (>30 ml);
(7)Heart, liver, or renal failure;
(8)Refusal to sign written informed consent;
(9)Unable to undergo randomized enrollment.
(10)Left handed.
(11)Continued bleeding at the time of acupuncture
administration.
Procedure
Eligible patients will be randomized to either study groups
(acupuncture plus conventional treatment) or control
groups (conventional treatment alone) based on the size
and side of their TH. After successful randomization,
neurological assessments will occur at four time points:
before treatment sessions begin, 30 days after onset of
TH, at the end of treatment (6 weeks), and 90 days after
onset of TH.
Intervention
Participants in both groups will receive conventional
Western medical treatments as recommended by the
guidelines for the management of spontaneous intracere-
bral hemorrhage including blood pressure management,
ICP monitoring, appropriate prophylaxis, and surgical
treatment as necessary for life-threatening hemorrhages
[2]. In addition to conventional treatment, patients in the
study group will receive 36 sessions (once a day, 6 days a
week for 6 weeks) of acupuncture.
Acupuncture
Acupuncture treatment will be started within 72 h after
TH onset, and applied once a day, 6 days a week for
6 weeks (a total of 36 sessions). The sessions will be
performed by an experienced acupuncture doctor with
over 10 years of working experience and 7 years of
acupuncture training. This doctor will also receive train-
ing prior to the start of the trial. The acupuncture proto-
col was designed by a Sichuan University Huaxi Hospital
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professor with more than 25 years of practical experi-
ence, in accordance with guidelines from published pa-
pers and clinical experience. It will follow the Standards
for Reporting Interventions in Clinical Trials for Acu-
puncture 2010 checklist, as shown in Table 1. Acupunc-
ture points are identified by the point location method
as described by the World Health Organization (WHO
standard) [33].
Both scalp and body acupuncture will be performed in
this trial. The parameters for scalp acupuncture will be
as follows: two or three needles penetrating through the
top midline, the motor region of the affected side, and
the sensory region on the side of the lesion. The acu-
points on the affected side of the body only and not on
the contralateral side will be as follows: LI15 (Jian Yu),
LI11 (Qu Chi), SJ5 (Wai Guan), and LI4 (He Gu) in the
upper extremity; ST34 (Liang Qiu), ST36 (Zu San Li),
GB34 (Yang Ling Quan), SP6 (San Yin Jiao), and LV3
(Tai Chong) in the lower extremity (Table 1). Additional
acupoints will be added as follows: RN23 (Lian Quan),
bilateral GB20 (Feng Chi), and ST9 (Ren Ying) for
dysphagia; ST6 (Jia Che) and ST5 (Di Cang) on the
affected side for facial paralysis (Table 2).
Stimulation will be applied to both the scalp and
body acupoints until the patient experiences de qi
(obtains qi). A patient’s experience of de qi may take
on multiple unique manifestations at the needle site
itself and/or around the site of needle manipulation
including soreness, aching, numbness, tingling, and
even warmth.
Huatuo brand needles (size 0.25 mm× 40 mm) made
by Suzhou Medical Appliances in Suzhou, Jiangsu prov-
ince, China, will be used to perform the acupuncture
treatments. Electrical stimulation of acupuncture needles
will be done at low frequency (1–3 Hz) in order to
ensure patient comfort.
Control group
Subjects in the control groups will not receive acupunc-
ture treatments. They will receive conventional TH
treatments only. Control group participants will then be
assessed neurologically at each follow-up visit.
Table 1 Acupoints to be used in the study
Acupoint Location Major indication and function
MS 5 (Dingzhonxian) At the top of the head, along the middle line of the
head, connecting DU 20 to DU 21.
Prolapse, sacral and lumbar problems,
paralysis, cortical polyuria, gastroptosis,
hyperostosis, hypertension
MS 6 (Dingnieqianxiexian) 1 cun anterior from DU 20 to GB 6. Treats motor function disorders
MS 7 (Dingniehouxiexian) 1 cun posterior to MS6, from DU 20 to GB 7. Treats sensory function disorders
LI15 (Jian Yu) On the shoulder girdle, in the depression between
the anterior end of the lateral border of the acromion
and the greater tubercle of the humerus.
Shoulder pain, paralysis
LI11 (Qu Chi) On the lateral aspect of the elbow, at the midpoint of
the line connecting LU5 with the lateral epicondyle
of the humerus.
Upper extremity palsies, relaxes and
strengthens tendons
SJ5 (Wai Guan) On the posterior aspect of the forearm, at the midpoint
of the interosseous space between the radius and the
ulna, 2 B-cun proximal to the dorsal wrist crease.
Tinnitus, paralysis of the arms, upper
extremity pain;
LI4 (He Gu) On the dorsum of the hand, in the depression radial
and proximal to the second metacarpophalangeal joint.
Spasm in the fingers
ST34 (Liang Qiu) On the anterolateral aspect of the thigh, between the
vastus lateralis muscle and the lateral border of the
rectus femoris tendon, 2 B-cun superior to the base
of the patella.
Gastrospasm, leg muscle atrophy
ST36 (Zu San Li) On the anterior aspect of the leg, on the line
connecting ST35 with ST41, 3 B-cun inferior to ST35.
Constipation or diarrhea, paralysis of the
lower limbs
GB34 (Yang Ling Quan) On the fibular aspect of the leg, in the depression
anterior and distal to the head of the fibula.
Inhibited ability to flex and stretch
SP6 (San Yin Jiao) On the tibial aspect of the leg, posterior to the medial
border of the tibia, 3 B-cun superior to the prominence
of the medial Malleolus.
Irregular menstruation, paralysis of the
lower limbs
LV3 (Tai Chong) On the dorsum of the foot, between the first and
second metatarsal bones, in the depression distal to
the junction of the bases of the two bones, over the
dorsalis pedis artery.
Hypertension, paralysis
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Table 2 Interventions details according to Standards for Reporting Interventions in Clinical Trials of Acupuncture
(STRICTA) guidelines
Item Detail Detail response
1. Acupuncture rationale
(Explanations and examples)
1a) Style of acupuncture (e.g. Traditional
Chinese Medicine, Japanese, Korean,
Western medical, Five Element, ear
acupuncture, etc)
Traditional needle acupuncture
1b) Reasoning for treatment provided,
based on historical context, literature
sources, and/or consensus methods,
with references where appropriate
Selected traditional acupuncture points
in the 12 meridian system and scalp
points based on literature review and
clinical experience
1c) Extent to which treatment
was varied
No variation
2. Details of needling
(Explanations and examples)
2a) Number of needle insertions per
subject per session (mean and range
where relevant)
13–19 insertions per session
2b) Names (or location if no standard
name) of points used (uni/bilateral)
Scalp points: motor region and sensory
region, unilateral on the side of the lesion
Acupoints on limbs:LI15 (Jian Yu), LI11
(Qu Chi), SJ5 (Wai Guan), LI4 (He Gu), ST34
(Liang Qiu), ST36 (Zu San Li), GB34 (Yang
Ling Quan), SP6 (San Yin Jiao), LV3 (Tai
Chong),all unilateral on the affected side
Modification: for dysphagia, GB20 (Feng
Chi), RN23 (Lian Quan), and ST9 (Ren Ying);
for facial paralysis, ST6 (Jia Che) and ST5
(Di Cang), unilateral on the affected side
2c) Depth of insertion, based on a
specified unit of measurement, or on
a particular tissue level
Depth of needle insertion is at least 5
to 10 mm
2d) Response sought (e.g. de qi or
muscle twitch response)
De-qi sensation felt by practitioner and subject
2e) Needle stimulation (e.g. manual, electrical) Manual
2f) Needle retention time 30 min
2 g) Needle type (diameter, length, and
manufacturer or material)
Needles: 0.25 × 40 mm, stainless steel




3a) Number of treatment sessions 36 sessions
3b) Frequency and duration of
treatment sessions
6 times per week, interval of 1 day
between sessions
4. Other components of treatment
(Explanations and examples)
4a) Details of other interventions administered
to the acupuncture group (e.g. moxibustion,
cupping, herbs, exercises, lifestyle advice)
None
4b) Setting and context of treatment,
including instructions to practitioners, and
information and explanations to patients
The same practitioner will treat every subject
every session at the patient’s bedside
5. Practitioner background
(Explanations and examples)
5) Description of participating
acupuncturists (qualification or professional
affiliation, years in acupuncture practice,
other relevant experience)
Licensed Traditional Chinese medicine
doctor at Huaxi Hospital of Sichuan
University with more than 10 years of
acupuncture treatment experience
6. Control or comparator interventions
(Explanations and examples)
6a) Rationale for the control or comparator
in the context of the research question,
with sources that justify this choice
No acupuncture will be performed on the
control group
6b) Precise description of the control or
comparator. If sham acupuncture or any
other type of acupuncture-like control is
used, provide details as for Items 1 to
3 above.
No sham acupuncture will be performed on
the control group
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Dropout criteria
Participants who meet any of the following criteria
will be removed from the study: (1) study group sub-
jects who miss more than three sessions (out of a
total of 36) of acupuncture; (2) patients who with-
draw their consent; (3) patients who experience
severe adverse events making their further inclusion
in the trial unsustainable; (4) patients whose neuro-
logical condition deteriorates making it difficult for
them to continue participating in the trial; (5)
patients who experience decompensation related to
accompanying and/or additional diseases; or (6)
patients whose further participation in the trial is




The primary outcome measure will be NIHSS score, a
measure of neurological status, at the end of treatment,
at 30 days after TH, and at 90 days after TH. NIHSS is
used to describe neurological deficits in stroke patients,
and it strongly predicts the likelihood of a patient’s
recovery after stroke. The NIHSS is comprised of 11 test
items including level of consciousness, gaze, visual field
defects, facial palsy, upper extremity motor, lower
extremity motor, limb ataxia, sensory ability, language,
dysphagia, and neglect. Total score ranges from 0 to 42,
with scores above 25 indicating very severe neurological
impairment, scores of 5 to 24 indicating moderately
severe to severe impairment, and scores below 5 indicat-
ing mild impairment.
Secondary outcome measures
Secondary outcome measures are as follows:
1. Poor outcome, defined as death or major disability,
is defined as a score of 3 to 6 on the modified
Rankin scale at 90 days after onset of TH. Scores on
the modified Rankin scale range from 0 to 6, with a
score of zero indicating no symptoms; a score of five
indicating severe disability, confinement to bed, or
incontinence; and a score of six indicating death.
2. The rate of surgery at 30 days is defined as the
incidence of neurological deterioration requiring
surgical intervention.
3. The Glasgow Outcome Scale (GOS) at 90 days after
onset of TH is a measure of long-term outcome and
includes five grades: 5, good recovery; 4, moderate
disability; 3, severe disability; 2, persistent vegetative
state; and 1, death.
4. The Barthel activities of daily living (ADL) index and
the Rivermead Mobility Index will be performed on
each patient at the end of treatment, at 30 days after
TH, and at 90 days after TH.
5. Patients with left thalamic hemorrhages will also be
evaluated with several language tests including the
Boston Naming Test, the Boston Diagnostic Aphasia
Exam, the Western Aphasia Battery, and the Mount
Wilga High Level Language Screening Test at the
end of treatment, at 30 days after TH, and at
90 days after TH.
6. Patients with right thalamic hemorrhages will also
be evaluated for visual neglect with the Behavioral
In-attention Test (BIT) at the end of treatment, at
30 days after TH, and at 90 days after TH.
Safety evaluation
Any adverse events or abnormalities will be recorded on
case report forms no matter what intervention is used.
The severity of such adverse events will be described as
mild, moderate, or severe, and the relation of the events
to the intervention will be evaluated as not related,
possibly related, or related. If any serious adverse events
occur as the result of a certain intervention, that inter-
vention will be stopped immediately and appropriate
corrective action will be taken. Any serious adverse
events will be reported promptly to the institutional
review board, according to the protocol.
Sample size calculation
Using the variable NIHSS score, the primary outcome
measure of the study, PS Power and Sample Size soft-
ware (version 3.0) was used to determine an appropriate
sample size for the study. In a previous study, NIHSS
scores in each subject group exhibited a normal distribu-
tion with a standard deviation of 4.2 points [11]. This as-
sumes a difference of 2.3 points between the groups, as
shown in a previous study on moderate TH. A sample
size of 488 provides 80% power (α = 0.05) to detect a
beneficial effect of early acupuncture therapy on the
primary outcome, assuming a 10% non-adherence to
treatment and a 3% loss to follow-up.
Statistical analysis
The results will be presented as mean score plus or
minus standard deviation and as percentages. Categor-
ical data will be analyzed with Fisher’s exact test or the
Mann-Whitney U test where appropriate. Continuous
data will be analyzed with the Student’s t test or
Pearson’s test where appropriate. Multi-ranked data will
be analyzed using the Mann-Whitney U test. Differences
will be considered statistically significant at P < 0.05
(two-tailed). All statistical analyses will be performed
using the Statistical Package for the Social Sciences
(version 13.0; SPSS; Chicago, Illinois, USA).
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Discussion
In this randomized controlled trial, we will observe the
effect of acupuncture therapy on patients with acute TH.
The findings of this project are expected to provide
evidence for the efficacy of acupuncture in improving
the prognosis of patients with moderate TH. To
minimize bias, stratified block randomization will be
used according to sex and age, and the outcomes re-
viewer will be blinded. Subjects will be treated alone in a
treatment room in order to avoid any communication
with other subjects.
Generally speaking, no ideal placebo-controlled acu-
puncture trials have been performed previously [34].
Because recent acupuncture trials have examined so-
called sham acupuncture techniques, including: needling
of acupuncture points through non-penetrating needles,
needling of non-acupuncture points, and needling of
acupuncture points that are not indicated for that spe-
cific condition, these prior trials have not accurately
reflected TCM theory and therefore have not properly
assessed it [34]. Further complicating things is that sham
acupuncture has been shown to have some efficacy [35].
In China, many patients and their families have had
acupuncture at some time in their lives or are at least
familiar with the acupuncture process. Therefore, it
would be difficult to design a trial assessing the utility of
sham acupuncture versus real acupuncture while keep-
ing the patient blinded.
The decision was made to examine patients with left
sided TH separately from patients with right sided TH.
In the majority of patients, Broca’s cortical area and
Wernicke’s cortical area are located in the left hemi-
sphere. Therefore, patients with left hemisphere stroke
(ischemic or hemorrhagic) are at risk for language defi-
cits. Similarly, patients with right sided insults are at risk
for symptoms of visual neglect. Both language deficits
and visual neglect can have a profound impact on the
way a patient responds to treatment and rehabilitation
of other neurologic deficits. Therefore, to account for
the potentially confounding effects of language deficits
and visual neglect respectively, patients were subdivided
into right and left TH subgroups.
Along the same lines, not all patients have their
language centers located in their left hemisphere. While
the majority of left handed patients have their language
centers in the left hemisphere, some do have them in
the right hemisphere. Therefore, in this study, we have
only included right handed patients.
Another potentially confounding factor is the involve-
ment of adjacent brain tissue as a secondary result of
the initial thalamic insult. Adjacent brain tissue can
necrose either directly via extension of the thalamic
bleed or indirectly via mass effect from the thalamic
bleed and/or edema related to the thalamic bleed. Areas
at specifically high risk include the genu of the internal
capsule which lies lateral to the thalamus, the posterior
limb of the internal capsule which lies posterolateral to
the thalamus, the anterior limb of the internal capsule
which lies anterolateral to the thalamus, and the peri-
thalamic/peri-ventricular white matter which lies superior
to the thalamus. Involvement of the genu of the internal
capsule, the posterior limb of the internal capsule, and
adjacent white matter could result in paralysis. Involve-
ment of the posterior limb of the internal capsule could
also result in sensory loss or impaired comprehension
[36]. Finally, involvement of the anterior limb of the
internal capsule could result in cognitive issues. Involve-
ment of any of these areas could potentially impact how a
patient recovers and/or sway the post-stroke assessment
scores in one direction or another depending on how
many of the affected patients ended up in the control
group or the intervention group. To combat this, we
utilized two mechanisms. First, we excluded patients from
the study whose TH on admission CT demonstrated
extension of the insult beyond the thalamus. However,
admission CT often does not disclose the true area
affected by the insult. CT performed 90 days later is much
more sensitive in demonstrating the insult’s true encom-
passment. We therefore further subdivided the groups by
size. While all subjects in the study have moderate
thalamic hemorrhage, groups were further subdivided into
subjects with 10–15 cc of TH and 15–30 cc of TH.
Patients with 10–15 cc of TH are much less likely to
experience insults to brain tissue external to the thalamus
than patients with 15–30 cc of TH as a result of the
smaller size of the initial bleed. We also plan to retrospect-
ively analyze the results of CT scans performed 90 days
following the insult to determine what percent of patients
in each group experienced extension of their primary
insult to tissue beyond the thalamus and how this may
have affected the results in that group. After dividing
patients by side of hemorrhage and size of hemorrhage
four intervention groups were established, and along with
the corresponding four control groups, this totaled eight
distinct subject groups.
Previous research has demonstrated that patients with
hand paresis only following stroke may not only be the
most likely to benefit from acupuncture therapy but also
the most likely to experience complete resolution of
their neurologic symptoms [37]. As a result, it is import-
ant, if able, to determine the results of our intervention
in patients with hand paresis only. As only patients with
moderate thalamic hemorrhage will be enrolled in this
trial, it is unlikely that our study will include many, if
any, subjects with hand paresis only. However, if there
are subjects with hand paresis, the results of our
intervention will be analyzed retrospectively following
conclusion of the trial.
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The primary outcome measure is NIHSS result. While
the NIHSS is a fine test, its comprehensiveness is some-
what lacking. In fact, previous studies examining inter-
ventions in stroke patients may have failed due to their
sole reliance on the NIHSS as an outcome measure [38].
Therefore, additional tests measuring paralysis, language,
visual neglect, and stroke outcome were also included in
this study.
Under strict quality control, this trial will attempt to
answer the question of whether or not acupuncture can
improve neurologic outcome following moderate TH.
Trial status
Recruitment commenced in January 2017, and it is an-
ticipated that the trial will be completed by March 2021.
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